A statistician's perspective on biomarkers in drug development

Pharmaceutical Statistics

Volumn 10, Issue 6, 2011, Pages 494-507

  Jenkins, Martin ^a   Flynn, Aiden ^b   Smart, Trevor ^c   Harbron, Chris ^a   Sabin, Tony ^d   Ratnayake, Jayantha ^e   Delmar, Paul ^f   Herath, Athula ^g   Jarvis, Philip ^a   Matcham, James ^d  

^a ASTRAZENECA   (United Kingdom)

^b EXPLORISTICS LTD   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d AMGEN LTD   (United Kingdom)

^e ROCHE PRODUCTS LTD   (United Kingdom)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

^g MEDIMMUNE   (United States)

Author keywords

biomarkers; personalized health care; safety biomarkers; statistics; surrogate endpoint

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; DECISION MAKING; DRUG DEVELOPMENT; MULTIVARIATE ANALYSIS; PERSONALIZED MEDICINE; PREDICTION; PROGNOSIS; STATISTICAL ANALYSIS;

BIOLOGICAL MARKERS; DRUG DISCOVERY; HUMANS; INDIVIDUALIZED MEDICINE; RESEARCH DESIGN; TOXICITY TESTS;

EID: 84855192071     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.532     Document Type: Article

References (109)

1. Atkinson AJ, et al,. (Biomarkers Definitions Working Group). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical Pharmacology and Therapeutics 2001; 69 (3): 89-95. (Pubitemid 32225406)
2. Mildvan D, Landay A, De Gruttola V, Machado S, Kagan J,. An approach to the validation of markers for the use in AIDS clinical trials. Clinical Infectious Diseases 1997; 24 (5): 764-74. (Pubitemid 27193852)
3. Lassere MN, et al,. Definitions and validation Criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. Journal of Rheumatology 2007; 34: 607-615. (Pubitemid 46364019)
4. Altar CA, et al,. A prototypical process for creating evidentiary standards for biomarkers and diagnostics. Clinical Pharmacology and Therapeutics 2008; 83 (2): 368-371.
5. De Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LWWM, Pienta KJ, Raghavan D,. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clinical Cancer Research 2008; 14 (19): 6302-6309.
6. Van Cutsem E, et al,. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine 2009; 360: 1408-1417.
7. Oldenhuis CNAM, Oosting SF, Gietema JA, De Vries EGE,. Prognostic versus Predictive value of Biomarkers in Oncology. European Journal of Cancer 2008; 44: 946-953.
8. Higgins JPT, Thompson SG, Spiegelhalter DJ,. A re-evaluation of random-effects meta-analysis. Journal of Royal Statistical Society A 2009; 172: 137-159.
9. Kyzas PA, Denexa-Kyza D, Ioannidis JPA,. Almost all articles on cancer prognostic markers report statistically significant results. European Journal of Cancer 2007; 43: 2559-2579. (Pubitemid 350086938)
10. Ioannidis JPA, Panagiotouo OA,. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. Journal of the American Medical Association 2011; 305 (21): 2200-2210.
11. Iannetti GD, Zambreanu L, Wise RG, Buchanan TJ, Huggins JP, Smart TS, Vennart W, Tracey I,. Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. PNAS (Proceedings of the National Academy of Science of the United States of America) 2005; 102: 18195-18200. (Pubitemid 41798524)
12. Arendt-Nielsen L, Frokjaer JB, Staahl C, Graven-Nielsen T, Huggins JP, Smart TS, Drewes AM,. Effects of Gabapentin on Experimental Somatic Pain and Temporal Summation. Molecular Pain 2007; 32: 382-388. (Pubitemid 47600012)
13. Arnow BA, Millheiser L, Garrett A, Lake Polan A, Glover GH, Hill KR, Lightbody A, Watson C, Banner L, Smart T, Buchanan T, Desmond JE,. Women with hypoactive sexual desire disorder compared to normal females: A functional magnetic resonance imaging study. Neuroscience 2009; 158: 484-502.
14. Keegan J, Horkaew P, Buchanan TJ, Smart TS, Yang GZ, Firmin DN,. Intra- and interstudy reproducibility of coronary artery diameter measurements in magnetic resonance coronary angiography. Journal of Magnetic Resonance Imaging 2004; 20: 160-166. (Pubitemid 38857530)
15. Kenward MG, Roger JH,. The use of baseline covariates in crossover studies. Biostatistics 2010; 11: 1-17.
16. Lee JW, et al,. Fit-for-purpose method development biomarker and validation for successful biomarker measurement. Pharmaceutical Research 2006; 23 (2): 312-328. (Pubitemid 43237862)
17. Moore HM, et al,. Advancing Cancer Research Through Biospecimen Science. Cancer Research 2009; 69 (17): 6770-6772.
18. Sparrow J, Hickson S,. Analyzing Laboratory Assay Data for Accuracy. SAS Conference Proceedings, Pittsburgh, PA, September, 14-17, 2008.
19. Dancey JE, et al,. Guidelines for the Development and Incorporation of Biomarker Studies in Early Clinical Trials of Novel Agents. Clinical Cancer Research 2010; 16: 1745.
20. Freidlin B, McShane LM, Korn EL,. Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute 2010; 102: 152-160.
21. De Noo ME, Tollenaar RA, Deelder AM, Bouwman LH,. Current status and prospects of clinical proteomics studies on detection of colorectal cancer: hopes and fears. World Journal of Gastroenterology 2006; 12 (41): 6594-6601. (Pubitemid 44794934)
22. Matt GE, Quintana PJ, Liles S, Hovell MF, Zakarian JM, Jacob 3rd P, Benowitz NL,. Evaluation of urinary trans-3′-hydroxycotinine as a biomarker of children's environmental tobacco smoke exposure. Biomarkers 2006; 11 (6): 507-523. (Pubitemid 44614823)
23. Mattsson N, Blennow K, Zetterberg H,. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. Clinical Chemistry and Laboratory Medicine 2010; 48 (5): 603-607.
24. Fenech M, et al,. Intra- and inter-laboratory variation in the scoring of micronuclei and nucleoplasmic bridges in binucleated human lymphocytes: Results of an international slide-scoring exercise by the HUMN project. Mutation Research 2003; 538: 185-186. (Pubitemid 36776701)
25. Clark-Langone KM, Wu JY, Sangli C, Chen A, Snable JL, Nguyen A, Hackett JR, Baker J, Yothers G, Kim C, Cronin MT,. Biomarker discovery for colon cancer using a 761 gene RT-PCR Assay. BMC Genomics 2007; 8: 279.
26. Hinestrosa MC, Dickersin K, Klein P, Mayer M, Noss K, Slamon D, Sledge G, Visco FM,. Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nature Reviews Cancer 2007; 7: 307-315.
27. O'Leary TJ,. Standardization in Immunohistochemistry. Applied Immunohistochemistry & Molecular Morphology 2001; 9 (1): 3-8. (Pubitemid 32179102)
28. Betsou F, ISBER Working Group on Biospecimen Science, et al. Human Biospecimen Research: Experimental Protocol and Quality Control Tools. Cancer Epidemiology, Biomarkers & Prevention 2009; 18: 1017-1025.
29. Carroll KJ,. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology. Pharmaceutical Statistics 2007; 6 (4): 253-260. (Pubitemid 350285117)
30. Long Q, et al,. Robust statistical methods for analysis of biomarkers measured with batch/experiment-specific errors. Statistics in Medicine 2010; 29: 361-370.
31. Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S,. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anti-Cancer Drugs 2007; 18 (9): 1093-1101. (Pubitemid 47294903)
32. Veneis P, McMichael AJ,. Bias and confounding in molecular epidemiological studies: special considerations. Carcinogenesis 1998; 19 (12): 2063-2067. (Pubitemid 29010242)
33. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM,. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. The New England Journal of Medicine 2003; 349: 335-342. (Pubitemid 36886239)
34. Klaren HM, Van't Veer LJ, Leeuwen FE, Rookus MA,. Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. Journal of the National Cancer Institute 2003; 95 (13): 941-947. (Pubitemid 36896711)
35. Arpino G, Wiechmann L,. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocrine Reviews 2008; 29 (2): 217-233. (Pubitemid 351519691)
36. Sequist LV, et al,. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Science Translational Medicine 2011; 3 (75): 75ra26.
37. Amado R, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman D, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson S, Chang D,. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. Journal of Clinical Oncology 2008; 26 (10): 1626-1634.
38. Hodgson D, Whittaker R, Herath A, Amakaye D, Clack G,. Biomarkers in oncology drug development. Molecular Oncology 2009; 3 (1): 24-32.
39. Benjamini Y, Hochberg Y,. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society, Series B 1995; 57 (1): 289-300.
40. Storey JD,. A direct approach to false discovery rates. Journal of the Royal Statistical Society, Series B 2002; 64: 479-498.
41. Tusher VG, Tibshirani R, Chu G,. Significance analysis of microarrays applied to the ionizing radiation response. PNAS (Proceedings of the National Academy of Science of the United States of America) 2001; 98: 5116-5121. (Pubitemid 32397092)
42. Talloen W, Clevert DA, Hochreiter S, Amaratunga D, Bijnens L, Kass S, Gohlmann HWH,. I/NI-calls for the exclusion of non-informative genes: A highly effective filtering tool for microarray data. Bioinformatics 2007; 23: 2897-2902. (Pubitemid 350162896)
43. Ploner A, Calza S, Gusnanto A, Pawitan Y,. Multidimensional local false discovery rate for microarray studies. Bioinformatics 2006; 22 (5): 556-565. (Pubitemid 43372816)
44. Harbron C,. A flexible probe level approach to improving the quality and relevance of Affymetrix microarray data. Presentation at the Non-Clinical Statistics Conference, Leuven, Belgium, September 25th 2008.
45. Wold S, Sjöström M, Eriksson L,. PLS-regression: a basic tool of chemometrics. Chemometrics and Intelligent Laboratory Systems 2001; 58: 109-130. (Pubitemid 33033283)
46. Parry RM, Jones W, Stokes TH, Phan JH, Moffitt RA, Fang H, Shi L, Oberthuer A, Fischer M, Tong W, Wang MD,. k-Nearest neighbor models for microarray gene expression analysis and clinical outcome prediction. The Pharmacogenomics Journal 2010; 10: 292-309.
47. Breiman L,. Random Forests. Machine Learning 2001; 45 (1): 5-32. (Pubitemid 32933532)
48. Cortes C, Vapnik V,. Support-Vector Networks. Machine Learning 1995; 20: 273-297.
49. Shi L,. et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nature Biotechnology 2010; 28 (8): 827-838.
50. Frueh F, Amur S, Mummaneni P, Epstein RS, Aubert RE, DeLuca TM, Verbrugge RR, Burckart GJ, Lesko LJ,. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 2008; 28 (8): 992-998.
51. Vogel CL, Franco SX,. Clinical experience with trastuzumab (Herceptin). The Breast Journal 2003; 9 (6): 452-462. (Pubitemid 37433210)
52. Tan GM, Wu E, Lam YY, Yan BP,. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics 2010; 11 (3): 439-448.
53. Hughes AR, Mosteller M, Bansal AT, Davies K, Haneline SA, Lai EH, Nangle K, Scott T, Spreen WR, Warren LL, Roses AD, CNA30027, CNA30032 study teams. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 2004; 5 (2): 203-211. (Pubitemid 38351278)
54. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS,. Cytochrome p-450 polymorphisms and response to clopidogrel. The New England Journal of Medicine 2009; 360 (4): 354-362.
55. Friedlin B, McShane LM, Korn E,. Randomized clinical trials with biomarkers: design issues. Journal of the National Cancer Institute 2010; 102: 152-160.
56. Simon R,. Advances in clinical trial designs for predictive biomarker discovery and validation. Current Breast Cancer Reports 2009; 1: 216-221.
57. Buyse M, Michiels S, Grothey A, Matheson A, De Gramont A,. Integrating biomarkers in clinical trials. Expert Review of Molecular Diagnostics 2011; 11 (2): 171-182.
58. Hoering A, LeBlanc M, Crowley JJ,. Randomized phase III clinical trial designs for targeted agents. Clinical Cancer Research 2008; 14 (14): 4358-4367.
59. George S,. Statistical issues in translational cancer research. Clinical Cancer Research 2008; 14 (19): 5954-5958.
60. Wang S-J, O'Neill RT, Hung HMJ,. Approaches to Evaluation of Treatment Effect in Randomised Clinical Trials with Genomic Subset. Pharmaceutical Statistics 2007; 6 (3): 227-244. (Pubitemid 47455262)
61. Freidlin B, Simon R,. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for Sensitive Patients. Clinical Cancer Research 2005; 11 (21): 7872-7878. (Pubitemid 41611633)
62. Jiang W, Freidlin B, Simon R,. Biomarker adaptive threshold design: a Procedure for Evaluating Treatment with Possible Biomarker-Defined Subset Effect. Journal of the National Cancer Institute 2007; 99 (13): 1036-1043. (Pubitemid 47232604)
63. FDA. Drug diagnostics co-development concept paper (Draft, August 2005). Available at:.
64. Schetz M, Dasta J, Goldstein S, Golper T,. Drug-induced acute kidney injury. Current Opinion in Critical Care 2005; 11: 555-565. (Pubitemid 41697327)
65. Ozer JS, Chetty R, Kenna G, Palandra J, Zhang Y, Lanevschi A, Koppiker N, Souberbielle BE, Ramaiah SK,. Enhancing the utility of alanine aminotransferase as a standard reference for drug-induced liver injury. Regulatory Toxicology and Pharmacology 2010; 56: 237-246.
66. FDA. Guidance for Industry: Drug-Induced Liver Injury: Premarketing Clinical Evaluation, 2009. Available at:.
67. The Predictive Safety Testing Consortium. Critical Path Institute. Available at:.
68. European Medicines Agency. Evaluation of Medicines for Human Use Innovative Drug Development Approaches Final Report from the EMEA/CHMP-Think-Tank Group on Innovative Drug Development, 22 March 2007. Available at:.
69. Institute of Medicine (IOM). Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. the National Academic Press: Washington DC, 2009. Available at:.
70. SAFE-T Consortium. Safer And Faster Evidence-based Translation.
71. Mattes WB, Walker EG, Abadie E, Sistare FD, Vonderscher J, Woodcock J, Woosley RL,. Research at the interface of industry, academia and regulatory science. Nature Biotechnology 2010; 28: 432-433.
72. Sistare FD et al. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nature Biotechnology 2010; 28: 446-454.
73. Valentin JP, Bialecki R, Ewart L, Hammond T, Leishmann D, Lindggren S, Martinez V, Pollard C, Redfern W, Wallis R,. A framework to assess the translation of safety pharmacology data to humans. Journal of Pharmacological and Toxicological Methods 2009; 60: 152-158.
74. Ewart L,. Conscious Dog Cardiovascular Telemetry Predictive Value to Man as Defined by the Animal Model Framework. Presentation at the Safety Pharmacology Society 11th Annual Meeting, Innsbruck, Austria, September 19-22, 2011.
75. Altman DG, Bland JM,. Diagnostic tests 2: predictive values. British Medical Journal 1994; 309: 102. (Pubitemid 24216428)
76. Jafarzadeha SR, Johnson WO, Utts JM, Gardner IA,. Bayesian estimation of the receiver operating characteristic curve for a diagnostic test with a limit of detection in the absence of a gold standard. Statistics in Medicine 2010; 29: 2090-2106.
77. Hsieh H-N, Su H-Y, Zhou X-H,. Interval estimation for the difference in paired areas under the ROC curves in the absence of a gold standard test. Statistics in Medicine 2009; 28: 3108-3123.
78. Joseph L, Gyorkos TW, Coupal L,. Bayesian Estimation of Disease Prevalence and the Parameters of Diagnostic Tests in the Absence of a Gold Standard. rican Journal of Epidemiology 1995; 141 (3): 263-272.
79. Choi Y-K, Johnson WO, Collins MT, Gardner IA,. Bayesian Inference for Receiver Operating Characteristic Curves in the Absence of a Gold Standard. Journal of Agricultural, Biological, and Environmental Statistics 2006; 11 (2): 210-229. (Pubitemid 43834221)
80. Bonventre JV, Vaidya VS, Schmouder R, Feig P, Dieterle F,. Next-generation biomarkers for detecting kidney toxicity. Nature Biotechnology 2010; 28 (5): 436-440.
81. Waikar SS, Betensky RA, Bonventre JV,. Creatinine as the gold standard for kidney injury biomarker studies? Nephrology Dialysis Transplantation 2009; 24: 3263-3265.
82. Matheis K, et al,. A generic operational strategy to qualify translational safety biomarkers. Drug DiscoveryToday In Press.
83. FDA. Guidance for Industry: Qualification Process for Drug Development Tools, October 2010. Available at:.
84. Qualification of Novel methodologies for Drug Development: Guidance to applicants, Jan 2009. Available at:.
85. Fleming TR, DeMets DL,. Surrogate endpoints in clinical trials: are we being misled? Annals of Internal Medicine 1996; 125: 605-613. (Pubitemid 126450094)
86. Fleming T,. Surrogate endpoints and FDA's accelerated approval process. Health Affairs 2005; 24 (1): 67-78. (Pubitemid 40173935)
87. Baker S, Kramer B,. A perfect correlate does not a surrogate make. BMC Medical Research Methodology 2003; 3: 16.
88. O'Hagan A, Stevens JW, Campbell MJ,. Assurance in clinical trial design. Pharmaceutical Statistics 2005; 4: 187-201. (Pubitemid 41358690)
89. Julious SA, Swank DJ,. Moving statistics beyond the individual clinical trial: applying decision science to optimize a clinical development plan. Pharmaceutical Statistics 2005; 4: 37-46. (Pubitemid 40425994)
90. Weir C, Walley R,. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Statistics in Medicine 2006; 25: 183-203. (Pubitemid 43141502)
91. Burzykowski T, Molenberghs G, Buyse M,. The evaluation of surrogate endpoints (statistics for biology and health). Springer: Berlin Heidelberg New York, 2005.
92. Prentice RL,. Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine 1989; 8: 431-440. (Pubitemid 19105891)
93. Freedman LS, Graubard BI, Schatzkin A,. Statistical validation of intermediate endpoints for chronic diseases. Statistics in Medicine 1992; 11: 167-178.
94. Hughes M, Daniels M,. Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine 1997; 16: 1965-1982. (Pubitemid 27397267)
95. Shi Q, Sargent D,. Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials. International Journal of Clinical Oncology 2009; 14: 102-111.
96. Li Y, Taylor J,. Predicting treatment effects using biomarker data in a meta-analysis of clinical trials. Statistics in Medicine 2010; 29: 1875-1889.
97. Buyse M, Molenberghs G,. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 1998; 54: 1014-1029. (Pubitemid 28429294)
98. Buyse M, Molenberghs G, Burzykowski T, Renard D, Geys H,. The validation of surrogate endpoints in meta-analyses of randomized experiments. Biostatistics 2000; 1 (1): 49-67.
99. Burzykowski T, Buyse M,. Surrogate threshold effect: an alternative measure for meta-analytic surrogate endpoint validation. Pharmaceutical Statistics 2006; 5: 173-186. (Pubitemid 44400217)
100. Buyse et al. Biomarkers and surrogate end points-the challenge of statistical validation. Nature Reviews Clinical Oncology 2010; 7: 309-317.
101. Hughes et al. CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. AIDS 1998; 12 (14): 1823-32.
102. Duffy S, Treasure FP,. Potential surrogate endpoints in cancer research-some considerations and examples. Pharmaceutical Statistics 2010; 10 (1): 34-39.
103. Nathan DM, et al,. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009; 32 (7): 1327-1334.
104. Nissen SE, Wolski K,. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England Journal of Medicine 2007; 356: 2457-2471. (Pubitemid 46919772)
105. Table of pharmacogenomic biomarkers in drug labels. Available at:.
106. Draft guidance for industry and food and drug administration staff-In vitro companion diagnostic devices, July 2011. Available at:.
107. Warnock D, Peck C,. A roadmap for biomarker qualification. Nature Biotechnology 2010; 28 (5): 444-445.
108. Dieterle F, Sistare F, Goodsaid F, et al,. Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nature Biotechnology 2010; 28 (5): 455-462.
109. Qualification opinion of Alzheimer's disease novel methodologies/ biomarkers for BMS-708163. Reference EMA/CHMP/SAWP/102001/2011. Draft consultation 2011. Available at:.